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Bromocriptine- associated ototoxicity*
by
PHILIPPE L. LANTHiER,t MARSHA Y. MORGAN % and JOHN BALLANTYNE§ (London)
Abstract
Three patients treated with bromocriptine for chronic hepatic encephalopathy showed
audiometric evidence of bilateral sensori-neural hearing-loss. Audiometrically, the
hearing improved in all three patients when the bromocriptine dosage was reduced, thus
suggesting that this drug may produce a reversible ototoxicity.
introduction
Bromocriptine (2-bromo-alpha-ergocryptine) is a
dopamine agonist which has been used success-
fully to treat Parkinsonism (Calne et al, 1978;
Parkes, 1979; Teychenne et al, 1982),
acromegaly (Sachdev et al, 1981; Moses et al,
1981; Quabbe, 1982), prolactinomas (Archer
et al, 1982; Editorial, 1982) and other 'non-
functioning' pituitary tumours (Johnston et al,
1981), mastodynia (Durning and Sellwood,
1982) and chronic hepatic encephalopathy
(Morgan et al, 1980). Early side-effects include
nausea, dizziness and postural hypotension.
Their occurrence can be largely circumvented by
slow introduction of the drug. Psychiatric
disturbances and erythromelalgia are associated
with prolonged use of the drug in high doses, but
occur infrequently.
We report the occurrence of a reversible
ototoxic effect in three patients treated with
bromocriptine for chronic hepatic encephalopathy.
Case Reports
Case 1
TSE, a male aged 52 years, presented in 1974
with alcoholic cirrhosis complicated by variceal
bleeding and hepatic encephalopathy. He settled
well with conservative management, but still
showed evidence of encephalopathy when
discharged from hospital. Over the next two years
his mental state remained poor despite abstinence
from alcohol, protein restriction to 40 g./day and
lactulose 40 ml/day. In October 1976 bromo-
criptine was introduced and increased over eight
weeks to a maintenance dose of 20 mg. daily. His
clinical condition improved remarkably and at
three months there was no subjective or objective
evidence of encephalopathy.
In November 1977 he installed new stereo-
phonic equipment at home. Over the next 15
months sound engineers visited repeatedly
because the patient, an accomplished musician,
complained that the equipment blunted the tonal
differences between instruments and blurred top
soprano and tenor notes. In May 1979, at the
suggestion of a sound engineer, he asked to have
his hearing tested. The audiogram showed
bilateral sensori-neural hearing-loss, most
marked in the high frequency range and suggestive
of drug ototoxicity (Fig. la). His plasma
bromocriptine concentration 90 minutes after a
5 mg. dose was 2.4 ng/ml, which is within the
normal therapeutic range. His plasma albumin
was 42 g./l. (reference range 35 to 55). The
patient refused to stop bromocriptine but agreed
to reduce the dose to 10 mg. daily over the next
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three months under careful supervisioa Little loss
of efficacy was observed Subjective improve-
ment in hearing was first noted in September 1979
and confirmed by an audiogram in December
1979 (Fig. lb). Further subjective improvement
occurred and was confirmed in audiograms
performed in March and September 1980. Since
that time his hearing has remained stable on
bromocriptine 10 mg. daily and an audiogram
performed in June 1983 showed no further
significant change (Fig. lc).
Case 2
NT, a male aged 25 years, presented in 1967
with cryptogenic cirrhosis and uncontrollable
variceal haemorrhage; an emergency porto-caval
shunt was performed In 1970 hepatic encephalo-
pathy was noted which responded reasonably well
to protein restriction 40 g./day and lactulose
20 to 40 ml./day. However, his condition later
deteriorated so that in the 12 months from March
1976 he was admitted on six occasions with
hepatic pre-coma. In March 1977 bromocriptine
was introduced and increased over six weeks to a
maintenance dose of 15 mg. daily. A dramatic
improvement in his clinical condition followed
He observed no change in his hearing, but a
screening audiogram in April 1980 showed slight
symmetrical, bilateral sensori-neural hearing-
loss, particularly at high frequencies, consistent
with drug ototoxicity (Fig. 2a). His plasma
bromocriptine concentration 90 minutes after a
5 mg. dose was 1.8 ng./ml. which is within the
normal therapeutic range. His plasma albumin
was 44 g./L The patient and his family refused to
stop bromocriptine and were only persuaded to
reduce the dosage to 10 mg. daily in November
1981 when a repeat audiogram showed no
change. Very little loss of efficacy was noted when
the drug dosage was reduced but the repeat
audiogram in June 1983 showed a slight but
definite improvement (Fig. 2b).
Case 3
AL, a male aged 59 years, presented in 1969
with hepatitis B associated cirrhosis complicated
by recurrent variceal haemorrhage. A porto-caval
shunt was performed following which he
developed hepatic encephalopathy. He initially
responded to protein restriction 40 g./day and
lactulose 40 ml./day, but the improvement was
ill-sustained. In April 1977 he started treatment
with bromocriptine, achieving a maintenance
dose of 15 mg. daily. His clinical condition
improved remarkably. He had not observed any
change in his hearing, but a screening audiogram
performed in April 1980 showed bilateral,
sensori-neural hearing-loss consistent with drug
ototoxicity (Fig. 3a). His plasma bromocriptine
concentration 90 minutes after a 5 mg, dose was
3.3 ng/ml. which is within the normal therapeutic
range. His plasma albumin was 40 g./l.
Bromocriptine was reduced to 10 mg. daily, with
little loss of efficacy, and a repeat audiogram in
August 1980 (Fig. 3b) showed deterioration in
the right ear but some improvement in the left ear.
The patient died suddenly in September 1980
following a myocardial infarction.
Discussion
All three patients described showed bilateral
high frequency hearing-loss whilst on treatment
with bromocriptine. None of the patients were
taking drugs known to be ototoxic, nor was there
evidence that they had done so previously. There
was no history of excessive exposure to noise nor
of previous ear problems. Reduction of the dose of
bromocriptine was followed by improvement in
the audiograms in two of the patients in both
ears and in the other patient in one ear. It
seems reasonable to suggest that the drug was
responsible for the reversible ototoxicity.
The doses of bromocriptine used to treat
chronic hepatic encephalopathy are modest
compared with those used in Parkinsonism
(Calne et al, 1978; Parkes, 1979), acromegaly
(Sachdev et al, 1981) and in the treatment of
prolactinomas (Archer et al, 1982). Despite the
fact that many patients have been exposed to
much higher doses of bromocriptine for as long or
longer than the patients reported here, no previous
reports of bromocriptine-associated ototoxicity
exist. It is possible that the ototoxicity may
go un-noticed, as only one of our three patients
experienced subjective hearing-loss and he
was an accomplished musician; the other two
were asymptomatic and their hearing-loss was
only detected on audiometry. Alternatively,
bromocriptine-associated ototoxicity may only
occur in patients in whom the drug is used to treat
chronic hepatic encephalopathy, this latter would
seem more likely.
Bromocriptine is incompletely absorbed from
the gastro-intestinal tract, metabolised in the liver
and mainly excreted in the bile. In plasma it is
90 to 96 per cent bound to albumin. In theory
bromocriptine metabolism might be disturbed inCLINICAL RECORDS 401
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FIG. 1
Serial audiograms in patient TSE.
(a)—May 1979, bilateral high frequency sensori-neural hearing-loss while taking bromocriptine 20 mg. daily,
(b)—December 1979, improvement in hearing-loss six months after reduction of bromocriptine dosage to 10 mg.
daily,
(c)—June 1983, sustained improvement in hearing on maintenance bromocriptine 10 mg. daily.402 P. L. LANTHIER, M. Y. MORGAN AND J. BALLANTYNE
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FIG. 2
Serial audiograms in patient NT.
(a)—April 1980, symmetrical, bilateral sensori-neural hearing-loss while taking bromocriptine 15 mg. daily,
(b)—June 1983, improvement in hearing-loss following reduction of bromocriptine dosage to 10 mg. daily in
November 1981.
patients with liver disease perhaps leading to
higher plasma concentrations for a given dose of
drug. However, plasma bromocriptine concen-
trations were within the normal therapeutic
range in all three patients and none was
hypoalbuminaemic.
The mechanism by which the ototoxicity arises
must of necessity be speculative. Other drugs
which may cause reversible ototoxic effects
include diuretics, especially ethacrynic acid and
frusemide; anti-protozoal agents, notably quinine
and chloroquine; and salicylates. In all these
instances, the damage is thought to be brought
about by vasoconstriction of the small vessels in
the microvasculature of the cochlea (Hawkins
et al, 1967). Indeed histopathological damage to
the stria vascularis has been seen in guinea-pigs
(Quick and Duvall, 1970), cats (Johnsson and
Hawkins, 1972) and a human subject (Arnold
et al, 1981) following the use of loop diuretics.
The ototoxicity occurring with bromocriptine
may also have a vascular origin.CLINICAL RECORDS 403
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FIG. 3
Serial audiograms in patient AL.
(a)—March 1980, bilateral high frequency sensori-neural hearing-loss whilst on bromocriptine 15 mg. daily,
(b)—August 1980, improvement in hearing-loss in the left ear five months after reduction of bromocriptine dosage to
10 mg. daily.
Patients on long-term treatment with bromo-
criptine should be screened for potential
ototoxicity and if necessary the drug dosage
reduced. Pre-treatment audiometry and regular
screening during therapy should be contemplated,
especially in patients with chronic hepatic
encephalopathy.
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